gens (MAAs) (Gattoni-Celli and Cole 1996; Zhai et al. 1996) is an important and often practiced adjuvant therapy for melanoma patients. It seems to be a more promising and safer approach than chemotherapy and radiotherapy (Saleh et al. 2005) . However, our initial expectations have been disappointing because of the low efficacy. One of the reasons for the unsuccessful therapy is that immuno-selection of antigen-negative tumor cells and silencing of MAAs occur, resulting in the evasion of immune surveillance and tumor escape (Cormier et al. 1998; Komenaka et al. 2004 ). Many immunotherapeutic investigations have focused on improving the effector side of the antitumor response, but only a few studies have been concerned with preventing the loss of MAAs expression.
To improve the efficacy of immunotherapy using cytotoxic lymphocytes (CTL), one possible solution is to up-regulate melanoma antigens to increase the sensitivity of melanoma cells to CTL. The loss of the ability to present antigen to T cells, for example, beta-2 microglobulin loss (D'Urso et al. 1991) , MHC class I loss (Ferrone and Marincola 1995) and expression loss of the transporter associated with antigen processing (TAP)-1 (Maeurer et al. 1996) , was reported. Some of these phenomena were caused by gene mutations and/or loss of the gene sequence in melanoma and are considered "irreversible" phenomena, and others were caused by loss/suppression of the antigen expression in melanoma by autocrine factors from the melanoma cell itself, and are considered "reversible" antigen loss (Kurnick et al. 2001) .
We would like to improve immunotherapy through increasing the MAAs expression by using drug/chemical compounds as modulators. To find effective modulators, the selection of candidates among many chemicals will be required at the first step. Therefore, we tried to make a fluorescent cellular reporter system for screening candidates by utilizing the promoter region of tumor antigen, Melan-A/MART-1, which is a glycoprotein associated with the melanosome, the organelle that is associated with melanin synthesis and is recognized by autologous cytotoxic T cells (Busam et al. 1998) .
In this paper, we report the successful construction of a screening system for investigating chemicals that can up-regulate the expression of Melan-A/MART-1 in melano-ma.
MATERIALS AND METHODS

Chemicals
The chemicals that we tried to screen were in the SCADS inhibitor kit 1 which was provided by Screening Committee of Anticancer Drugs (SCAD), The Cancer Chemotherapy Center of Japanese Foundation for Cancer Research, supported by Grant-in-Aid for Scientific Research on Priority Area "Cancer" from The Ministry of Education, Culture, Sports, Science and Technology, Japan. The kit was a 96-well plate set with 94 chemicals of various inhibitors for searching unknown biological activities that are listed in the website (http://gantoku-shien.jfcr.or.jp/kit.html).
For additional experiments after the screening, we used chemicals purchased from several companies as follow: U0126 was from Cell Signaling Technology (Beverly, MA) and cytochalasin D, daunorubicin HCl, and doxorubicin HCl were all from Wako (Osaka, Japan). All chemicals were dissolved in non-toxic concentrations of dimethyl sulfoxide (DMSO) (Wako) just before addition into the cell culture medium.
Cell lines and cell culture
The MU89 cell line originated from a human melanoma that expressed antigens of Melan-A/MART-1, gp100, and tyrosinase as previously described (Kurnick et al. 2001) . The low-antigen variant MUX was derived from MU89 (Kurnick et al. 2001) . MM96L + and MM96L -were derived from MM96L of human melanoma (Pope et al. 1979) . Following the spontaneous divergence of the original cell line in culture into separate antigen-positive and low-antigen populations, these cells were cloned by limited dilution and termed MM96L + and
MM96L
-based on the presence or the absence of melanocytic antigens such as MART1 and gp100 (Kono et al. 2006 ). These four melanoma cells were kindly provided by Dr. J.T. Kurnick. A375 of human melanoma was purchased from DS Pharma Biomedical Co., Ltd (Osaka, Japan) and SK-MEL-28 (RCB1930) of human melanoma was provided by the RIKEN CELL BANK (Tsukuba, Japan). All cells except for SK-MEL-28 were cultured at 37°C in 5% CO 2, in Dulbecco's modified minimum essential medium (DMEM, Sigma-Aldrich, St. Louis, MO), supplemented with 10% fetal bovine serum and 50 μ g/mL gentamicin. The culture medium of SK-MEL-28 was minimum essential medium (MEM, Sigma-Aldrich), supplemented with 10% fetal bovine serum and 50 μ g/mL gentamicin. The other culture conditions for SK-MEL-28 were the same as for the other cell lines.
Melan-A/MART-1 promoter reporter system
The 235-bp, 1267-bp and 2811-bp segments of human genomic DNA containing Melan-A/MART-1 promoter regions ( Fig. 1) were amplified by polymerase chain reaction (PCR) with a proof-reading polymerase, Platimun PCR superMix High Fidelity (Invitrogen, Carlsbad, CA), using the primers listed in Table 1 . The PCR products were recombined into pGlow-TOPO vector (Invitrogen, Carlsbad, CA) to confirm the sequences, then recombined into pAcGFP1-1 vector (Clontech, Palo Alto, CA) at the Bgl II site. To compare the promoter activities, MU89 of Melan-A/MART-1 positive melanoma was transiently transfected with these constructs individually by Nucleofector ® (amaxa biosystems, Gaithersburg, MD) and the GFP fluorescence was measured by flow cytometry (FACS Calibur, BD Biosciences, San Jose, CA) after 48 and 72 hr incubation. After the evaluation of the 3 promoters, pAcGFP1-1-235 bp Melan-A/MART-1 promoter was linearized by ApaL I digestion before stable transfection. This construct was transfected into melanoma cells by Nucleofector® and incubated in G418 (Geneticin, Invitrogen, Carlsbad, CA) containing medium. The pAcGFP1-1 vector had a neomycin-resistance cassette and it allowed stably transfected cells to be selected using G418. Stable transfectants were cloned by limited dilution.
Fluorescent staining and flow cytometric analysis
To evaluate the expression of each cytoplasmic melanoma antigen (Ag) in the melanoma cell lines, the cells were fixed with 1 ml of 2% paraformaldehyde for 10 min at room temperature and then, after adding 9 ml of 100% methanol, incubated on ice for 30 min before washing twice and blocking with 4% fetal bovine serum (FBS) for 10 min. Then mouse monoclonal antibodies (mAb) specific for Melan-A/MART-1 (Novocastra Laboratories Ltd, Newcastle, UK) were added to the cells for 45 min at room temperature. After washing, the cells were stained for 30 min with fluorescein isothiocianate (FITC)-conjugated anti-mouse IgG Ab (Zymed Laboratories, Inc., South San Francisco, CA). The stained cells were analyzed by flow cytometry. Histograms and mean channel fluorescence were calculated using Cell Quest Pro software (BD Biosciences, San Jose, CA).
The geometoric channel fluorescence values are shown relative to the untreated control value, which was assigned as a baseline of 1.0.
DNA and RNA experiments
Genomic DNA for cloning the Melan-A/MART-1 promoter region was isolated from melanoma cells by using a QIAamp DNA kit (Qiagen, Valencia, CA), and total RNAs from melanoma cell lines were extracted using RNeasy ® Mini Kit (Qiagen, Valencia, CA).
cDNA synthesis was done with TaqMan ® Reverse Transcription Reagents (Applied Biosystems, Foster city, CA). For quantitative PCR, the total volume of each reaction was 25 μ l, including 12.5 μ l of qPCR Master Mix plus low ROX (Eurogentec, TABLE 1. The Sequences of Primers for cloning of Melan-A/MART-1 promoter region.
Oligo name Sequence
MART-1 promoter 235bp.F 5'-TAAAATAAATGGCTTCCCTAGGATAGAGCA-3'
San Diego, CA), the optimal amount of primer and probe, and 25 ng of template. Real-time PCR (45 cycles at 95°C for 15 seconds and at 60°C for 1 minute; after initial heat activation at 95°C for 10 minutes)
was done with the Mx3000P TM Real-Time PCR System (Stratagene, La Jolla, CA, USA). Data were analyzed with MxPro QPCR software (Stratagene, La Jolla, CA, USA). All quantitative PCR data were pre- (Butterfield et al. 1997 ) is a gray box followed by exon 1. Vertical bar indicates a CANNTG basic helix-loop-helix (bHLH) sequence. The three proximal bHLH elements were reported by Butterfield et al. (1997) . Du et al. (2003) reported that E-1 and E-2 box had the bHLH sequence where the microphthalmia transcript factor ( 
RESULTS
Establishment of screening system
To establish a rapid screening system for detecting chemicals that enhance the Melan-A/MART-1 production, the appropriate sequence of the promoter gene should be determined. Therefore, we first compared the promoter activity among the three promoters of different lengths, as shown in Fig. 1A . The pAcGFP1-1 vectors with the 235-bp, 1267-bp or 2811-bp promoter regions for Melan-A/ MART-1 and empty vector as negative control were transfected into MU89, a Melan-A/MART-1-positive melanoma cell line. We detected the fluorescence of GFP in transfected cells by flow cytometry after 48 and 72 hrs.
The fluorescence of the vector with the 235-bp promoter was as high as that of the 1267-bp promoter after 48-hr culture and its intensity continued after 72 hrs, although that of the 1267-bp promoter decreased after 72 hrs. The 2811-bp promoter showed less activity than both the 235-bp and the 1267-bp promoter, as shown in Fig. 1B . As the 235-bp promoter showed higher activity than the other two, it was chosen for the next transfection experiments.
To construct the system, the pAcGFP1 vector with the 235-bp promoter was transfected into MUX cells, Melan-A/ MART-1 and gp100 negative melanoma cells. We obtained 6 colonies responsive to U0126, a MEK inhibitor, which is known to enhance the Melan-A/MART-1 expression in melanoma cells (Kono et al. 2006 ). After incubation with 10 μ M of U0126 for 72 h, clones #3, 5 and 9 showed high fluorescence as shown in Fig. 2 . And the #9 clone was adopted as the reporter cell because it showed the most rapid and stable growth compared to the other clones #3 and #5 after their successive cultures. Oligo name Sequence
Evaluation of GFP screening system
DQ stands for Eclipsec Dark Quencher (Nippon EGT, Toyama, Japan)
MART-1 promoter (MUX#9) in 96-well plates (Becton Dickinson Labware, Franklin Lakes, NJ). After incubation of the cells for 72h, we analyzed the response of the Melan-A/MART-1 promoter by flow cytometry and the morphological changes due to cytotoxicity by microscopy. When a chemical induced no augmentation of fluorescence without cytotoxicity, a five-through ten-fold concentration of the chemical was examined at the next step. When the cytotoxicity of a chemical was too strong, we then retested at onetenth of the concentration. Among 94 agents examined, 100 μ M of daunorubicin HCl and doxorubicin HCl showed high fluorescence intensity, and 100 μ M of cytochalasin D revealed a similar stimulatory effect on U0126, as shown in Fig. 3 . To confirm whether or not the three chemicals really stimulate the Melan-A/MART-1 promoter of melanoma cells, the protein and mRNA expressions were examined in 6 kinds of melanoma cell lines, MU89, MM96L
+ , SK-MEL-28, MUX, MM96L -, and A375. As shown in Table 3 , all cell lines showed to various increases of protein and mRNA expression, and the mean values of their augmentation rates were similar to the results obtained in the screening system as shown in Fig. 3, i. e., daunorubicin HCl and doxorubicin HCl showed high augmenting activity and cytochalasin D revealed a mild stimulatory effect. It is remarkable that not only antigen presenting cells of MU89, MM96L
+ and SK-MEL-28, but also low-antigen presenting cells of MUX, MM96L
-and A375 responded well to the 3 chemicals.
DISCUSSION
Immunotherapy for melanoma has been directed at melanocytic differentiation antigens such as Melan-A/ MART-1, gp100, tyrosinase, and TRP-1, which are recognized by CTL. But we know that these melanoma antigens are diminished in many patients. Therefore, a strategy to Daunorubicin, HCl 3.8 ± 0.6 1.7 ± 0.2 5.6 ± 0.6 1.7 ± 0.2 1.9 ± 0.3 1.7 ± 0.2 8.0 ± 1.4 3.7 ± 1.7 4.1 1.7 Doxorubicin, HCl 3.4 ± 1.0 1.9 ± 0.2 5.5 ± 0.7 1.9 ± 0.2 1.4 ± 0.2 4.3 ± 0.3 7.3 ± 0.4 3.6 ± 1.3 4.2 1.9
Data indicate relative values to that of each cells cultured with no chemical (as untreated), and they are expressed as the mean ± standard error of three independent experiments. U0126 was exceptionally examined once.
* and ** indicate that each cell line usually reveals high and low expression of Melan-A/MART-1 protein, respectively.
induce and enhance the tumor antigens is needed for improving the efficacy of melanoma immunotherapy. In this study, we developed a screening system that can monitor the promoter-enhancing activity by measuring the amount of GFP produced. It was fast and economical to use this system compared to other traditional methods such as the luciferase promoter assay and the intracellular staining of melanoma antigen by antibody. This system was effective and inexpesnsive for a large screening experiment. This time we chose Melan-A/MART-1 as the MAA for the screening of augmenting chemicals. Melan-A/MART-1 is a highly immunogenic human antigen recognized by CTL (Kawakami and Rosenberg 1997; Romero et al 2002) . It was reported that Melan-A/MART-1 was required for the maturation of melanosomes (Hoashi et al. 2005) , though the function of Melan-A/MART-1 in melanocyte development and differentiation still remains to be clarified. Melan-A/ MART-1 is expressed in normal immature melanocytes and in more than 90% of fresh melanoma tumors and melanoma cell lines (Berset et al. 2001; van Dinten et al. 2005) . Many epitopes of Melan-A/MART-1 were reported and used for peptide vaccine therapy of melanoma in practice. Actually, all known Melan-A/MART-1 epitopes were HLA-A2 restricted, except one restricted to HLA-B45 (Schneider et al. 1998 ). To recognize Melan-A/MART-1 as MAA, MHC class I type matching between the host and epitope is essential. The highest allele frequency is A24 (32.7-35.6%) and the second is A2 (23.0-24.8%) in Japanese (Tokunaga et al. 1997; Tanaka et al. 1996) . On the other hand, A2 is found in 50% of Caucasians (Ellis et al. 2000) . Compared to Caucasian, Melan-A/MART-1 seems to be less useful for Japanese because of a lower frequency of HLA-A2. There may be a disadvantage of using Melan-A/MART-1 promoter as a representative MAA. However, Kono et al. (2006) reported that U0126 increased not only Melan-A/MART-1 but also gp100 and tyrosinase expression in many melanoma cell lines. We also have preliminary data showing that several augmenting agents for Melan-A/MART-1 expression also increased other MAAs such as gp100, TRP-1 and tyrosinase. As gp100 and tyrosinase are known to have A24 restricted epitopes in addition to A2, these augmenting agents may be expected to be useful to examine the possibility of improving the efficacy of immunotherapy for patients lacking the A2 allele.
Another reason for choosing Melan-A/MART-1 was that its promoter region has already been investigated closely (Butterfield et al. 1997; van Dinten et al. 2005) . Butterfield et al. (1997) reported that the promoter activity of Melan-A/MART-1 exists in a 233-bp fragment, and van Dinten et al. (2005) demonstrated that the 2956-bp promoter construct showed two-time higher activity than the 286-bp promoter, and that the 1373-bp promoter showed far less activity than the other two. On the other hand, Dunn et al. (2007) reported that the 1200-bp promoter worked well. In our comparison among the 235-bp, 1267-bp and 2811-bp Melan-A/MART-1 promoters, the 235-bp promoter showed the highest activity even after culture of 72 hr. Thus, we adopted the 235-bp promoter in our screening system. Disagreements on the results among four laboratories are probably due to differences in the lengths of the promoters used, since the tertiary structure of the promoter region probably varies in function along with small differences in its length, or since there may possibly exist unknown cis elements in the region. Actually, regarding on four E-boxes illustrated in Fig. 1A , there is no difference in the number of E-boxes between the 235-bp and 286-bp, and 1267-bp and 1373-bp, and the 2811-bp and 2956-bp promoter in our experiment and van Dinten et al. (2005) , respectively.
We tried to obtain the same fragments, which were used in earlier studies (Butterfield et al. 1997; van Dinten et al. 2005 ), but could not. One reason is that the PCR machine could not amplify the same fragments that they used, probably due to unsuitable PCR primers, and another reason may be that the same restriction enzymes that they used were not applied in our experiment.
We established a stable cell line of MUX transfected with the 235-bp Melan-A/MART-1 promoter to rapidly screen drugs that enhance the expression of Melan-A/ MART-1 in melanoma. Three chemicals screened by the cells actually increased the production of Melan-A/MART-1 protein and mRNA in all 6 melanoma cells, and their increasing rates were well proportional to their fluorescence intensities observed in the screening system as shown in Fig. 3 , which confirmed the reliability of the screening system.
The biological functions of the three chemicals are as follows. Daunorubicin and doxorubicin are known to interact with DNA by intercalation and inhibition of macromolecular biosynthesis, which inhibits the progression of the enzyme topoisomerase II (Gewirtz 1999) . Cytochalasin D is a potent inhibitor of actin polymerization, which causes arrest of the cell cycle at the G1-S transition. The common molecular mechanism by which the three chemicals increase the Melan-A/MART-1 production cannot be explained at present and remains to be solved in the future.
By using our established screening system, we would like to try to find several candidate chemicals that up-regulate the tumor antigen expression, and will further examine the efficacy of such candidates on immunotherapy in mice with melanoma towards finding future clinical applications.
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